(Q36677456)

15 August 2017

1 reference

title

Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib (English)

1 reference

15 August 2017

main subject

chronic myeloid leukemia

0 references

2

Hagop Kantarjian

1 reference

15 August 2017

3

Jorge Cortes

1 reference

15 August 2017

author name string

Alfonso Quintás-Cardama

series ordinal

1

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 December 2006

1 reference

15 August 2017

1 reference

15 August 2017

volume

2

1 reference

15 August 2017

issue

6

1 reference

15 August 2017

page(s)

655-665

1 reference

15 August 2017

cites work

Cancer statistics, 2004

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

Effect of mutational inactivation of tyrosine kinase activity on BCR/ABL-induced abnormalities in cell growth and adhesion in human hematopoietic progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

A model of human p210(bcr/ABL)-mediated chronic myelogenous leukemia by transduction of primary normal human CD34(+) cells with a BCR/ABL-containing retroviral vector

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

SH1 domain autophosphorylation of P210 BCR/ABL is required for transformation but not growth factor independence

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

The NH(2)-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by Bcr-Abl

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

Cell cycle targets of Ras/Raf signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

Src family tyrosine kinases and growth factor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

The interaction of the Bcr-Abl tyrosine kinase with the Src kinase Hck is mediated by multiple binding domains

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

The Src family kinase Hck interacts with Bcr-Abl by a kinase-independent mechanism and phosphorylates the Grb2-binding site of Bcr

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

Overriding imatinib resistance with a novel ABL kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.6.655

21 January 2018

Identifiers

DOI

10.2217/14796694.2.6.655

1 reference

15 August 2017

1 reference